비교리스트

 카트 문의
시장보고서
상품코드
1663468

세계의 생물제제 수탁 개발 시장 : 서비스 유형별, 생물제제 유형별, 최종사용자별, 국가별, 지역별 - 산업 분석, 시장 규모 및 점유율, 예측(2025-2032년)

Biologics Contract Development Market, By Service Type, By Biologics Type, By End-User, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
발행일: | 리서치사: AnalystView Market Insights | 페이지 정보: 영문 303 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

리포트 하이라이트

생물제제 수탁 개발 시장 규모는 2024년에 75억 965만 달러에 달하며, 2025-2032년에 CAGR 8.94%로 확대

생물제제 수탁 개발 시장 역학

개인맞춤형 의료에 대한 수요 증가가 바이오의약품 위탁개발 성장 견인

맞춤형 의료에 대한 수요 증가는 생물제제 위탁 개발 시장의 큰 촉진요인입니다. 개인맞춤의료는 개인의 유전자 프로파일에 맞게 치료를 조정하여 효능을 향상시키고 부작용을 줄입니다. 미국 국립보건원(NIH)에 따르면 맞춤의료 세계 시장은 2025년까지 3조 5,000억 달러에 달할 것으로 예상됩니다.

생물학적 치료법이 맞춤의료의 핵심으로 떠오르면서 전문적인 위탁개발 서비스의 필요성이 증가하고 있습니다. NIH는 전 세계 인구의 약 10명 중 1명이 희귀질환을 앓고 있으며, 이들 중 상당수가 생물학적 치료법을 필요로 하는 것으로 추정하고 있습니다. 이러한 요인으로 인해 바이오 제약사들은 필요한 전문지식을 활용하고 효율적으로 생산 규모를 확대하기 위해 위탁 개발 기관과 제휴하고 있습니다.

생물학적제제 위탁개발 시장 : 주요 인사이트

리서치 애널리스트의 분석에 따르면 세계 시장은 예측 기간(2025-2032년) 동안 약 8.94%의 연평균 복합 성장률(CAGR)로 매년 성장할 것으로 예상됩니다.

서비스 유형별로는 수탁제조이 2024년 가장 큰 시장 점유율을 보일 것으로 예상됩니다.

생물제제 유형별로는 2024년 모노클로널 항체가 주요 생물제제 유형이 될 것으로 예상됩니다.

지역별로는 북미가 2024년 매출을 창출할 주요 시장입니다.

생물제제 위탁개발 시장 : 세분화 분석

세계 바이오의약품 위탁개발 시장은 서비스 유형, 바이오의약품 유형, 최종사용자, 지역을 기준으로 세분화됩니다.

시장은 서비스 유형에 따라 위탁 연구, 수탁제조, 위탁 시험의 세 가지 범주로 나뉩니다. 생물제제 위탁개발 시장에서 가장 지배적인 부문은 수탁제조입니다. 이 부문은 단클론 항체 및 백신과 같은 생물제제의 대량 생산에 대한 수요 증가로 인해 크게 성장하고 있습니다. 수탁제조기관(CMO)은 바이오의약품을 효율적으로 제조하는 데 필요한 전문지식, 시설, 장비를 바이오제약기업에 제공하면서 규제 준수를 유지하면서 바이오의약품을 생산할 수 있도록 지원합니다. 생물제제는 세포배양, 발효 등 특수한 공정이 필요하므로 이러한 서비스를 아웃소싱함으로써 기업은 비용과 시장 출시 시간을 단축할 수 있습니다. 특히 맞춤형 의료와 복잡한 질병에 대한 생물학적 치료의 부상으로 확장 가능한 제조 솔루션의 필요성이 증가함에 따라 이 분야의 중요성이 더욱 부각되고 있습니다.

시장은 생물제제 유형에 따라 모노클로널 항체, 백신, 유전자치료제, 유전자 재조합단백질, 재조합단백질 등 4가지 카테고리로 분류됩니다. 바이오의약품 위탁개발 시장에서 가장 큰 비중을 차지하는 부문은 모노클로널 항체입니다. 이 부문은 암, 자가면역질환, 감염성 질환을 포함한 다양한 질환의 치료에 대한 모노클로널 항체(mAb) 수요 증가로 인해 시장을 주도하고 있습니다. mAbs는 특이성이 높고, 기존 약물에 비해 더 나은 효능과 적은 부작용을 제공하는 표적 치료제를 제공합니다. 바이오기술의 발전과 함께 많은 새로운 mAb가 개발되어 맞춤형 의료에 널리 사용되고 있습니다. 그 결과, 의약품 개발 수탁기관(CDO)은 mAb 개발 및 제조 서비스 제공에 점점 더 집중하고 있으며, 이 분야는 생물제제 위탁 개발 시장에서 가장 두드러진 위치를 차지하고 있습니다.

생물학적제제 위탁개발 시장 : 지역별 분석

북미는 탄탄한 의료 인프라, 강력한 R&D 역량, 생물제제에 대한 높은 수요에 힘입어 생물제제 위탁개발 시장에서 큰 비중을 차지하고 있습니다. 미국 식품의약국(FDA)은 생물제제 규제에 있으며, 중요한 역할을 하고 있으며, 치료의 안전성과 유효성을 보장하고 있습니다. 북미에는 주요 바이오 제약사, 학술기관, 위탁 개발 기관이 있으며, 생물제제 개발의 중요한 거점이 되고 있습니다. 미국은 암, 자가면역질환 등 만성질환의 발병률이 높아 생물제제에 대한 수요가 더욱 가속화되고 있습니다. 또한 이 지역의 의료 정책은 개인맞춤형 의료의 혁신과 상환을 지원하고 있으며, 이는 생물제제에 대한 막대한 투자를 유도하고 있습니다. 제조 및 개발 서비스를 전문 CDO에 아웃소싱하는 추세도 시장 성장에 박차를 가하고 있습니다. 유전체학 및 바이오테크놀러지의 발전으로 북미는 생물제제 개발 및 위탁 서비스 분야에서 선도적인 위치를 차지하고 있습니다.

미국은 첨단화된 의료 시스템, 주요 제약사, 최첨단 연구기관으로 인해 생물제제 위탁개발 시장에서 지배적인 역할을 하고 있습니다. 미국 식품의약국(FDA)은 생물제제의 안전성과 유효성을 보장하는 확립된 규제 프레임워크를 제공하여 시장에 대한 신뢰를 조성하고 있습니다. 미국에서는 암, 당뇨병, 자가면역질환 등 만성질환의 유병률이 높아 생물학적 치료제에 대한 수요가 증가하고 있습니다. 또한 미국은 생명공학 및 의약품 혁신의 세계 리더로서 맞춤의료, 유전자치료, 모노클로널 항체 등에 대한 투자가 활발히 이루어지고 있습니다. 생물제제의 개발 및 제조를 개발업무수탁기관(CDO)에 위탁하는 경향이 강화되고 있으며, 바이오제약기업은 비용을 절감하고 기술 혁신에 집중할 수 있습니다. 또한 미국 정부의 연구비 지원과 규제 측면의 특혜가 시장 상황을 더욱 강화시키고 있습니다. 정밀의료에 대한 관심이 높아짐에 따라 미국 바이오의약품 위탁개발 시장은 앞으로도 강력한 성장세를 유지할 것으로 예상됩니다.

생물학적제제 위탁개발 시장 : 경쟁 구도

바이오의약품 위탁 개발 시장의 경쟁 환경은 첨단 기술, 규제 준수, 비용 효율적인 솔루션에 초점을 맞춘 여러 주요 기업의 존재가 특징이며, Lonza Group, WuXi AppTec, Samsung Biologics와 같은 주요 기업은 공정 개발, 제조, 임상시험 지원을 포함한 광범위한 서비스 제공을 통해 시장을 선도하고 있습니다. 임상시험 지원을 포함한 생물제제 개발의 광범위한 서비스 제공으로 시장을 선도하고 있습니다. 예를 들어 론자 그룹은 대규모 바이오의약품 생산, 특히 단클론 항체의 대규모 생산에 있으며, 최첨단 장비와 전문지식을 제공합니다. 우시 앱텍은 맞춤형 의료에 중점을 둔 신약 발굴, 개발, 제조의 통합 서비스로 유명합니다. 삼성바이오로직스는 최첨단 바이오 제조 역량과 업무 효율성 및 규제 준수에 중점을 두고 있습니다. 삼성바이오로직스는 제약사 및 바이오테크놀러지 기업과 긴밀한 관계를 유지하며 바이오의약품 개발 분야에서 우선순위 파트너로 자리매김하고 있습니다. 생산 규모 확대, 철저한 품질관리, 진화하는 규제 기준에 적응할 수 있는 능력은 경쟁 우위를 지속적으로 강화하고 있습니다.

목차

제1장 생물제제 수탁 개발 시장 개요

  • 조사 범위
  • 시장 추정 기간

제2장 개요

  • 시장 내역
  • 경쟁 인사이트

제3장 생물제제 수탁 개발의 주요 시장 동향

  • 시장 성장 촉진요인
  • 시장 성장 억제요인
  • 시장 기회
  • 시장의 향후 동향

제4장 생물제제 수탁 개발 시장 : 산업 분석

  • PEST 분석
  • Porter's Five Forces 분석
  • 시장 성장 전망 : 지도제작
  • 규제 체제 분석

제5장 생물제제 수탁 개발 시장 : 높아지는 지정학적 긴장의 영향

  • COVID-19 팬데믹의 영향
  • 러시아·우크라이나 전쟁의 영향
  • 중동 분쟁의 영향

제6장 생물제제 수탁 개발 시장 구도

  • 생물제제 수탁 개발 시장 점유율 분석(2024년)
  • 주요 제조업체별 내역 데이터
    • 기존 기업의 분석
    • 신규 기업의 분석

제7장 생물제제 수탁 개발 시장 : 서비스 유형별

  • 개요
    • 부문별 점유율 분석 : 서비스 유형별
    • 수탁 연구
    • 수탁제조
    • 수탁 시험

생물제제 수탁 개발 시장 : 생물제제 유형별

  • 개요
    • 부문별 점유율 분석 : 생물제제 유형별
    • 모노클로널 항체
    • 백신
    • 유전자 치료
    • 재조합 단백질

제8장 생물제제 수탁 개발 시장 : 최종사용자별

  • 개요
    • 부문별 점유율 분석 : 최종사용자별
    • 제약 기업
    • 바이오테크놀러지 기업
    • 학술·연구기관

제9장 생물제제 수탁 개발 시장 : 지역별

  • 서론
  • 북미
    • 개요
    • 북미의 주요 제조업체
    • 미국
    • 캐나다
  • 유럽
    • 개요
    • 유럽의 주요 제조업체
    • 독일
    • 영국
    • 프랑스
    • 이탈리아
    • 스페인
    • 네덜란드
    • 스웨덴
    • 러시아
    • 폴란드
    • 기타
  • 아시아태평양(APAC)
    • 개요
    • 아시아태평양의 주요 제조업체
    • 중국
    • 인도
    • 일본
    • 한국
    • 호주
    • 인도네시아
    • 태국
    • 필리핀
    • 기타
  • 라틴아메리카(LATAM)
    • 개요
    • 라틴아메리카의 주요 제조업체
    • 브라질
    • 멕시코
    • 아르헨티나
    • 콜롬비아
    • 기타
  • 중동 및 아프리카(MEA)
    • 개요
    • 중동 및 아프리카의 주요 제조업체
    • 사우디아라비아
    • 아랍에미리트
    • 이스라엘
    • 터키
    • 알제리
    • 이집트
    • 기타

제10장 주요 벤더 분석 : 생물제제 수탁 개발업계

  • 경쟁 대시보드
    • 경쟁 벤치마킹
    • 경쟁 포지셔닝
  • 기업 개요
    • Lonza Group
    • WuXi AppTec
    • Samsung Biologics
    • Catalent
    • Boehringer Ingelheim
    • AbbVie
    • Fujifilm Diosynth Biotechnologies
    • CordenPharma
    • Samsung Biologics
    • Patheon(Thermo Fisher Scientific)
    • Merck KGaA
    • KBI Biopharma
    • Recipharm
    • Minaris Regenerative Medicine
    • Syngene International
    • Rentschler Biopharma
    • Almac Group
    • Emergent BioSolutions

제11장 AnalystView의 전방위적 분석

KSA 25.03.13

REPORT HIGHLIGHT

Biologics Contract Development Market size was valued at US$ 7,509.65 Million in 2024, expanding at a CAGR of 8.94% from 2025 to 2032.

The biologics contract development market refers to the industry where companies outsource the development and manufacturing of biologic drugs to specialized service providers. Biologics are complex products derived from living organisms, including monoclonal antibodies, vaccines, and gene therapies. Contract development organizations (CDOs) offer services ranging from early-stage research, process development, and clinical trials, to large-scale manufacturing. These partnerships help biopharma companies reduce costs, improve efficiency, and access specialized expertise. As the demand for biologics grows, driven by advancements in personalized medicine and rare diseases, the biologics contract development market continues to expand, with companies focusing on regulatory compliance, innovation, and cost-effective solutions.

Biologics Contract Development Market- Market Dynamics

Rising demand for personalized medicine driving biologics contract development growth.

The rising demand for personalized medicine is a significant driver for the biologics contract development market. Personalized medicine tailors' treatments to individual genetic profiles, improving efficacy and reducing adverse effects. According to the U.S. National Institutes of Health (NIH), the global market for personalized medicine is projected to reach $3.5 trillion by 2025.

As biological therapies are central to personalized medicine, the need for specialized contract development services grows. The increasing prevalence of genetic disorders and cancer further fuels demand for biologics, with the NIH estimating that about 1 in 10 people globally are living with a rare disease, many requiring biological treatments. These factors have pushed biopharma companies to partner with contract development organizations to access the necessary expertise and scale production efficiently.

Biologics Contract Development Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 8.94% over the forecast period (2025-2032)

Based on Service Type segmentation, Contract Manufacturing was predicted to show maximum market share in the year 2024

Based on Biologics Type segmentation, Monoclonal Antibodies were the leading Biologics Type in 2024

Based on region, North America was the leading revenue generator in 2024

Biologics Contract Development Market- Segmentation Analysis:

The Global Biologics Contract Development Market is segmented based on Service Type, Biologics Type, End-User, and Region.

The market is divided into three categories based on Service Type: Contract Research, Contract Manufacturing, and Contract Testing. The most dominant segment in the biologics contract development market is Contract Manufacturing. This segment has seen substantial growth due to the increasing demand for large-scale production of biological drugs, including monoclonal antibodies and vaccines. Contract manufacturing organizations (CMOs) provide biopharma companies with the expertise, facilities, and equipment needed to produce biologics efficiently while maintaining regulatory compliance. As biologic therapies require specialized processes, such as cell culture and fermentation, outsourcing these services helps companies reduce costs and time-to-market. The need for scalable manufacturing solutions, particularly with the rise of personalized medicine and biological therapies for complex diseases, has solidified the importance of this segment.

The market is divided into four categories based on Biologics Type: Monoclonal Antibodies, Vaccines, Gene Therapies, and Recombinant Proteins. The most dominant segment in the biologics contract development market is Monoclonal Antibodies. This segment leads due to the growing demand for monoclonal antibodies (mAbs) in the treatment of various conditions, including cancer, autoimmune disorders, and infectious diseases. mAbs are highly specific, offering targeted therapies that provide better efficacy and fewer side effects compared to traditional drugs. With advancements in biotechnology, many new mAbs have been developed, contributing to their widespread use in personalized medicine. As a result, contract development organizations (CDOs) are increasingly focused on providing services for the development and manufacturing of mAbs, making this segment the most prominent in the biologics contract development market.

Biologics Contract Development Market- Geographical Insights

North America holds a significant share of the biologics contract development market, driven by the robust healthcare infrastructure, strong research capabilities, and the high demand for biologic therapies. The U.S. Food and Drug Administration (FDA) plays a critical role in regulating biologics, ensuring the safety and efficacy of treatments, which boosts confidence in the market. North America is home to several leading biopharma companies, academic institutions, and contract development organizations, making it a key hub for biologics development. The U.S. has a high incidence of chronic diseases, including cancer and autoimmune disorders, which further accelerates the demand for biologic treatments. Additionally, the region's healthcare policies support innovation and reimbursement for personalized medicine, attracting significant investments in biologics. The increasing trend of outsourcing manufacturing and development services to specialized CDOs also adds to the market's growth. With advancements in genomics and biotechnology, North America is positioned to continue leading in biologics development and contract services.

The United States plays a dominant role in the biologics contract development market, driven by its advanced healthcare system, leading pharmaceutical companies, and cutting-edge research institutions. The U.S. Food and Drug Administration (FDA) provides a well-established regulatory framework that ensures the safety and efficacy of biological products, fostering confidence in the market. The country has a high prevalence of chronic diseases such as cancer, diabetes, and autoimmune disorders, which propels the demand for biological treatments. Furthermore, the U.S. is a global leader in biotechnology and pharmaceutical innovation, with significant investments in personalized medicine, gene therapies, and monoclonal antibodies. The increasing trend of outsourcing biologic development and manufacturing to contract development organizations (CDOs) allows biopharma companies to reduce costs and focus on innovation. Moreover, the U.S. government's support for research funding and regulatory incentives further strengthens the market landscape. With a growing emphasis on precision medicine, the biologics contract development market in the U.S. is expected to continue its strong growth trajectory.

Biologics Contract Development Market- Competitive Landscape:

The competitive landscape of the biologics contract development market is marked by the presence of several key players focusing on advanced technologies, regulatory compliance, and cost-effective solutions. Companies like Lonza Group, WuXi AppTec, and Samsung Biologics lead the market with their extensive service offerings in biologic drug development, including process development, manufacturing, and clinical trial support. Lonza Group, for example, offers state-of-the-art facilities and expertise in large-scale biologics production, particularly for monoclonal antibodies. WuXi AppTec is known for its integrated services across drug discovery, development, and manufacturing, with a strong emphasis on personalized medicine. Samsung Biologics combines cutting-edge biomanufacturing capabilities with a focus on operational efficiency and regulatory adherence. These companies maintain strong relationships with pharmaceutical firms and biotechnology companies, positioning themselves as preferred partners in the biologic development space. Their ability to scale production, ensure quality control, and adapt to evolving regulatory standards continues to fuel their competitive advantage.

Recent Developments:

In February 2023, Lonza expanded its footprint in the U.S. with the establishment of a new laboratory focused on developing drugs in the early stages of clinical trials.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Lonza Group
  • WuXi AppTec
  • Samsung Biologics
  • Catalent
  • Boehringer Ingelheim
  • AbbVie
  • Fujifilm Diosynth Biotechnologies
  • CordenPharma
  • Samsung Biologics
  • Patheon (Thermo Fisher Scientific)
  • Merck KGaA
  • KBI Biopharma
  • Recipharm
  • Minaris Regenerative Medicine
  • Syngene International
  • Rentschler Biopharma
  • Almac Group
  • Emergent BioSolutions

GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET, BY SERVICE TYPE- MARKET ANALYSIS, 2019 - 2032

  • Contract Research
  • Contract Manufacturing
  • Contract Testing

GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET, BY BIOLOGICS TYPE- MARKET ANALYSIS, 2019 - 2032

  • Monoclonal Antibodies
  • Vaccines
  • Gene Therapies
  • Recombinant Proteins

GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Pharmaceutical Companies
  • Biotechnology Companies
  • Academic & Research Institutions

GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Biologics Contract Development Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Biologics Contract Development Market Snippet by Service Type
    • 2.1.2. Biologics Contract Development Market Snippet by Biologics Type
    • 2.1.3. Biologics Contract Development Market Snippet by End-User
    • 2.1.4. Biologics Contract Development Market Snippet by Country
    • 2.1.5. Biologics Contract Development Market Snippet by Region
  • 2.2. Competitive Insights

3. Biologics Contract Development Key Market Trends

  • 3.1. Biologics Contract Development Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Biologics Contract Development Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Biologics Contract Development Market Opportunities
  • 3.4. Biologics Contract Development Market Future Trends

4. Biologics Contract Development Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Biologics Contract Development Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Biologics Contract Development Market Landscape

  • 6.1. Biologics Contract Development Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Biologics Contract Development Market - By Service Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Service Type, 2024 & 2032 (%)
    • 7.1.2. Contract Research
    • 7.1.3. Contract Manufacturing
    • 7.1.4. Contract Testing

Biologics Contract Development Market - By Biologics Type

  • 7.2. Overview
    • 7.2.1. Segment Share Analysis, By Biologics Type, 2024 & 2032 (%)
    • 7.2.2. Monoclonal Antibodies
    • 7.2.3. Vaccines
    • 7.2.4. Gene Therapies
    • 7.2.5. Recombinant Proteins

8. Biologics Contract Development Market - By End-User

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By End-User, 2024 & 2032 (%)
    • 8.1.2. Pharmaceutical Companies
    • 8.1.3. Biotechnology Companies
    • 8.1.4. Academic & Research Institutions

9. Biologics Contract Development Market- By Geography

  • 9.1. Introduction
    • 9.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 9.2. North America
    • 9.2.1. Overview
    • 9.2.2. Biologics Contract Development Key Manufacturers in North America
    • 9.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.2.4. North America Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 9.2.5. North America Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
    • 9.2.6. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.2.7. The U.S.
      • 9.2.7.1. Overview
      • 9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.2.7.3. U.S. Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.2.7.4. U.S. Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.2.7.5. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.2.8. Canada
      • 9.2.8.1. Overview
      • 9.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.2.8.3. Canada Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.2.8.4. Canada Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.2.8.5. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 9.3. Europe
    • 9.3.1. Overview
    • 9.3.2. Biologics Contract Development Key Manufacturers in Europe
    • 9.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.3.4. Europe Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 9.3.5. Europe Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
    • 9.3.6. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.3.7. Germany
      • 9.3.7.1. Overview
      • 9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.7.3. Germany Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.3.7.4. Germany Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.3.7.5. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.3.8. UK
      • 9.3.8.1. Overview
      • 9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.8.3. UK Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.3.8.4. UK Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.3.8.5. UK Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.3.9. France
      • 9.3.9.1. Overview
      • 9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.9.3. France Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.3.9.4. France Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.3.9.5. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.3.10. Italy
      • 9.3.10.1. Overview
      • 9.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.10.3. Italy Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.3.10.4. Italy Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.3.10.5. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.3.11. Spain
      • 9.3.11.1. Overview
      • 9.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.11.3. Spain Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.3.11.4. Spain Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.3.11.5. Spain Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.3.12. The Netherlands
      • 9.3.12.1. Overview
      • 9.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.12.3. The Netherlands Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.3.12.4. The Netherlands Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.3.12.5. The Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.3.13. Sweden
      • 9.3.13.1. Overview
      • 9.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.13.3. Sweden Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.3.13.4. Sweden Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.3.13.5. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.3.14. Russia
      • 9.3.14.1. Overview
      • 9.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.14.3. Russia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.3.14.4. Russia Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.3.14.5. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.3.15. Poland
      • 9.3.15.1. Overview
      • 9.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.15.3. Poland Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.3.15.4. Poland Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.3.15.5. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.3.16. Rest of Europe
      • 9.3.16.1. Overview
      • 9.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.16.3. Rest of the Europe Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.3.16.4. Rest of the Europe Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.3.16.5. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 9.4. Asia Pacific (APAC)
    • 9.4.1. Overview
    • 9.4.2. Biologics Contract Development Key Manufacturers in Asia Pacific
    • 9.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.4.4. APAC Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 9.4.5. APAC Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
    • 9.4.6. APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.4.7. China
      • 9.4.7.1. Overview
      • 9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.7.3. China Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.4.7.4. China Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.4.7.5. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.4.8. India
      • 9.4.8.1. Overview
      • 9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.8.3. India Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.4.8.4. India Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.4.8.5. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.4.9. Japan
      • 9.4.9.1. Overview
      • 9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.9.3. Japan Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.4.9.4. Japan Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.4.9.5. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.4.10. South Korea
      • 9.4.10.1. Overview
      • 9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.10.3. South Korea Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.4.10.4. South Korea Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.4.10.5. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.4.11. Australia
      • 9.4.11.1. Overview
      • 9.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.11.3. Australia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.4.11.4. Australia Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.4.11.5. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.4.12. Indonesia
      • 9.4.12.1. Overview
      • 9.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.12.3. Indonesia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.4.12.4. Indonesia Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.4.12.5. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.4.13. Thailand
      • 9.4.13.1. Overview
      • 9.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.13.3. Thailand Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.4.13.4. Thailand Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.4.13.5. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.4.14. Philippines
      • 9.4.14.1. Overview
      • 9.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.14.3. Philippines Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.4.14.4. Philippines Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.4.14.5. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.4.15. Rest of APAC
      • 9.4.15.1. Overview
      • 9.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.15.3. Rest of APAC Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.4.15.4. Rest of APAC Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.4.15.5. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 9.5. Latin America (LATAM)
    • 9.5.1. Overview
    • 9.5.2. Biologics Contract Development Key Manufacturers in Latin America
    • 9.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.5.4. LATAM Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 9.5.5. LATAM Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
    • 9.5.6. LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.5.7. Brazil
      • 9.5.7.1. Overview
      • 9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.7.3. Brazil Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.5.7.4. Brazil Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.5.7.5. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.5.8. Mexico
      • 9.5.8.1. Overview
      • 9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.8.3. Mexico Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.5.8.4. Mexico Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.5.8.5. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.5.9. Argentina
      • 9.5.9.1. Overview
      • 9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.9.3. Argentina Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.5.9.4. Argentina Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.5.9.5. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.5.10. Colombia
      • 9.5.10.1. Overview
      • 9.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.10.3. Colombia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.5.10.4. Colombia Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.5.10.5. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.5.11. Rest of LATAM
      • 9.5.11.1. Overview
      • 9.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.11.3. Rest of LATAM Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.5.11.4. Rest of LATAM Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.5.11.5. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 9.6. Middle East and Africa (MEA)
    • 9.6.1. Overview
    • 9.6.2. Biologics Contract Development Key Manufacturers in the Middle East and Africa
    • 9.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.6.4. MEA Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 9.6.5. MEA Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
    • 9.6.6. MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.6.7. Saudi Arabia
      • 9.6.7.1. Overview
      • 9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.7.3. Saudi Arabia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.6.7.4. Saudi Arabia Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.6.7.5. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.6.8. UAE
      • 9.6.8.1. Overview
      • 9.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.8.3. UAE Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.6.8.4. UAE Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.6.8.5. UAE Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.6.9. Israel
      • 9.6.9.1. Overview
      • 9.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.9.3. Israel Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.6.9.4. Israel Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.6.9.5. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.6.10. Turkey
      • 9.6.10.1. Overview
      • 9.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.10.3. Turkey Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.6.10.4. Turkey Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.6.10.5. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.6.11. Algeria
      • 9.6.11.1. Overview
      • 9.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.11.3. Algeria Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.6.11.4. Algeria Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.6.11.5. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.6.12. Egypt
      • 9.6.12.1. Overview
      • 9.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.12.3. Egypt Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.6.12.4. Egypt Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.6.12.5. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 9.6.13. Rest of MEA
      • 9.6.13.1. Overview
      • 9.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.13.3. Rest of MEA Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 9.6.13.4. Rest of MEA Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 9.6.13.5. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)

10. Key Vendor Analysis- Biologics Contract Development Industry

  • 10.1. Competitive Dashboard
    • 10.1.1. Competitive Benchmarking
    • 10.1.2. Competitive Positioning
  • 10.2. Company Profiles
    • 10.2.1. Lonza Group
    • 10.2.2. WuXi AppTec
    • 10.2.3. Samsung Biologics
    • 10.2.4. Catalent
    • 10.2.5. Boehringer Ingelheim
    • 10.2.6. AbbVie
    • 10.2.7. Fujifilm Diosynth Biotechnologies
    • 10.2.8. CordenPharma
    • 10.2.9. Samsung Biologics
    • 10.2.10. Patheon (Thermo Fisher Scientific)
    • 10.2.11. Merck KGaA
    • 10.2.12. KBI Biopharma
    • 10.2.13. Recipharm
    • 10.2.14. Minaris Regenerative Medicine
    • 10.2.15. Syngene International
    • 10.2.16. Rentschler Biopharma
    • 10.2.17. Almac Group
    • 10.2.18. Emergent BioSolutions

11. 360 Degree AnalystView

12. Appendix

  • 12.1. Research Methodology
  • 12.2. References
  • 12.3. Abbreviations
  • 12.4. Disclaimer
  • 12.5. Contact Us
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제